Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Starch × Clear all

Phase

Status

Sponsor Class

OTHER 7 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Gastrointestinal 1

Conditions

Gastrointestinal Toxicity 1

Interventions

pembrolizumab 1023 Carboplatin 958 Paclitaxel 934 Gemcitabine 787 Cisplatin 751 Docetaxel 692 Bevacizumab 634 Nivolumab 518 Pemetrexed 502 Capecitabine 471 Cyclophosphamide 463 Fluorouracil 417 Dexamethasone 402 Rituximab 389 Oxaliplatin 346 Injections 338 atezolizumab 312 Trastuzumab 312 Cetuximab 286 Leucovorin 285 Irinotecan 265 130-nm albumin-bound paclitaxel 254 Prednisone 250 Ipilimumab 241 Doxorubicin 240 Lenalidomide 229 Fulvestrant 220 durvalumab 210 fludarabine 208 Erlotinib Hydrochloride 196

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351089 2020-03-05

ProRad

Probi AB

Phase NA Terminated

GastrointestinalGynecologic

Gastrointestinal Toxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡